Insulet develops, manufactures, and markets the Omnipod Insulin Management System for people that have diabetes. This system ...

Tandem Diabetes Care, Inc.’s Control-IQ+ Technology, used with the t:slim and Mobi insulin pumps, becomes the second AID ...

Insulet (NASDAQ:PODD – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research ...

Insulet Corporation (PODD), headquartered in Acton, Massachusetts, operates as an innovative medical device company. Valued ...

Stock analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for Insulet in a research note ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

For 2025, Insulet expects revenue growth between 16% and 20%. It projects Omnipod sales to increase by 17%-21%.

The company produces and sells Omnipod, an automated insulin delivery device, which works without the need for external ...

Insulet forecasts total company revenue growth of 16%-20% for 2025, with Omnipod revenue growth projected at 17%-21%. U.S. Omnipod revenue is expected to grow 16%-20%, driven by the continued ramp-up ...

For the year ending December 31, 2025, the Company expects revenue growth of 16% to 20%. Revenue growth ranges by product line are: Total ...

For the quarter ending March 31, 2025, the Company expects revenue growth of 22% to 25%. Revenue growth ranges by product line are: Total ...